BioCryst Pharmaceuticals, Inc. (BCRX) Price Target Analysis
Wall Street analyst price targets, ratings consensus & upside potential · Updated May 1, 2026
Current Price
$8.90
Price Target
$17.00
Target Range
$9.00 — $25.00
Analyst Rating
Buy
Forward P/E32.9x
Trailing P/E7.4x
Forward PEG—
Implied Growth+114.3%
Median Target$17.00
Analyst Spread94.1%
Price Forecast (1 Year)
Last 12 months price action with 12-month analyst target path
Bear Case
$9
+1.1%
Consensus
$17
+91.0%
Bull Case
$25
+180.9%
BCRX Price Target Analysis
Updated May 8, 2026As of May 8, 2026, BioCryst Pharmaceuticals, Inc. (BCRX) has a Wall Street consensus price target of $17.00, based on estimates from 29 covering analysts. With the stock currently trading at $8.90, this represents a potential upside of +91.0%. The company has a market capitalization of $1.87B.
Analyst price targets range from a low of $9.00 to a high of $25.00, representing a 94% spread in expectations. The median target of $17.00 aligns closely with the consensus average. The wide target spread reflects significant disagreement on fair value.
The current analyst consensus rating is Buy, with 25 analysts rating the stock as a Buy or Strong Buy,4 rating it Hold, and 0 rating it Sell or Strong Sell. This overwhelmingly bullish sentiment suggests analysts see significant catalysts for upside ahead.
From a valuation perspective, BCRX trades at a trailing P/E of 7.4x and forward P/E of 32.9x. Analysts expect EPS to grow +114.3% over the next year.
Investment Context: Price targets represent analyst expectations for the next 12 months and should be considered alongside your own research. Targets are based on analysts' assumptions about earnings growth, margins, and market conditions which may change. For sector-specific context, view other Healthcare stocks.
Analyst Sentiment Comparison
Industry Peer AnalysisAvg Peer Upside+34.1%
Avg Forward P/E32.4x
Peers with Coverage10 / 10
| Company | Market Cap | Price | Target | Upside | Rating | Fwd P/E | Analysts |
|---|---|---|---|---|---|---|---|
 RAREUltragenyx Pharmaceutical Inc. | $2.6B | $26.13 | $51.50 | +97.1% | Buy | — | 33 |
 FOLDAmicus Therapeutics, Inc. | $4.5B | $14.49 | $14.50 | +0.1% | Buy | 40.6x | 24 |
 ACADACADIA Pharmaceuticals Inc. | $3.9B | $22.57 | $34.78 | +54.1% | Buy | 50.9x | 37 |
 PTCTPTC Therapeutics, Inc. | $5.3B | $64.49 | $89.67 | +39.0% | Buy | — | 26 |
 KYMRKymera Therapeutics, Inc. | $6.9B | $84.63 | $117.06 | +38.3% | Buy | — | 26 |
 ARGXargenx SE | $48.7B | $787.31 | $1052.30 | +33.7% | Buy | 30.0x | 36 |
 HALOHalozyme Therapeutics, Inc. | $7.7B | $65.19 | $78.33 | +20.2% | Buy | 8.1x | 27 |
 PRAXPraxis Precision Medicines, Inc. | $9.6B | $333.28 | $544.40 | +63.3% | Buy | — | 16 |
 AKROAkero Therapeutics, Inc. | $4.5B | $54.65 | $48.40 | -11.4% | Buy | — | 14 |
 KALVKalVista Pharmaceuticals, Inc. | $1.4B | $26.72 | $28.50 | +6.7% | Buy | — | 13 |
Upside Potential Comparison
RAREPRAXACADPTCTKYMRARGXHALOKALVSee BCRX's True Return
Price is only half the story. See total return with reinvested dividends.
Launch CalculatorIs BCRX Undervalued?
DCF intrinsic value, peer multiples, and analyst estimates — see what the stock is really worth.
View ValuationCompare BCRX vs DBVT
Side-by-side business, growth, and profitability comparison vs DBV Technologies S.A..
Start ComparisonBCRX — Frequently Asked Questions
Quick answers to the most common questions about buying BCRX stock.
What is the BCRX stock price target for 2026?
The consensus Wall Street price target for BCRX is $17, representing 91.0% upside from the current price of $8.9. With 29 analysts covering the stock, this strong upside suggests significant value not yet reflected in today's share price.
Is BCRX a buy, sell, or hold?
BCRX has a consensus rating of "Buy" based on 29 Wall Street analysts. The rating breakdown is predominantly bullish, with 25 Buy/Strong Buy ratings. The consensus 12-month price target of $17 implies 91.0% upside from current levels.
Is BCRX stock overvalued or undervalued?
BCRX trades at a forward P/E of 32.8899x, representing a moderate valuation. With analysts targeting $17 (91.0% implied move), the stock appears reasonably valued with upside.
How high can BCRX stock go?
The most bullish Wall Street analyst has a price target of $25 for BCRX, while the most conservative target is $9. The consensus of $17 represents the median expectation. These targets typically reflect 12-month expectations.
How many analysts cover BCRX stock?
BCRX is heavily covered by Wall Street, with 29 analysts providing price targets and ratings. Of these, 0 have Strong Buy ratings, 25 have Buy ratings, 4 recommend Hold, and 0 have Sell or Strong Sell ratings. Higher analyst coverage generally indicates greater institutional interest and more reliable consensus estimates.
What is the BCRX stock forecast?
The 12-month BCRX stock forecast based on 29 Wall Street analysts shows a consensus price target of $17, with estimates ranging from $9 (bear case) to $25 (bull case). The median consensus rating is "Buy".
What is BCRX's forward P/E ratio?
BCRX trades at a forward P/E ratio of 32.9x based on next-twelve-months earnings estimates compared to a trailing P/E of 7.4x. The higher forward P/E suggests near-term earnings pressure. A forward P/E is useful for comparing valuations when earnings are expected to change significantly.
Should I buy BCRX stock?
Wall Street analysts are very optimistic on BCRX, with a "Buy" consensus rating and $17 price target (91.0% upside). 25 of 29 analysts rate it Buy or Strong Buy. This information is for educational purposes only. Always conduct your own research, consider your financial situation, and consult a financial advisor before making investment decisions.
Why do BCRX price targets vary so much?
BCRX analyst price targets range from $9 to $25, a 94% wide spread indicating significant analyst disagreement. Differences stem from varying assumptions about revenue growth, profit margins, competitive dynamics, and valuation multiples. The $17 consensus represents the middle ground.